Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Cumberland Pharmaceuticals shares rose above their 200-day moving average, reaching $7.14 and last trading at $7.03 versus the $5.96 average.
• Despite the technical move, analyst sentiment remains negative: Weiss Ratings reiterated a “sell (D-)” rating, and MarketBeat reports a consensus “Sell” rating.
• The company’s latest quarter showed significant weakness, with an adjusted loss of $0.20 per share versus an expected loss of $0.13 and revenue of just $0.17 million against an $8.50 million estimate.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) shares passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $5.96 and traded as high as $7.14. Cumberland Pharmaceuticals shares last traded at $7.03, with a volume of 30,401 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a research report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has a consensus rating of "Sell".

Cumberland Pharmaceuticals Trading Up 0.7%

The company has a market capitalization of $105.33 million, a price-to-earnings ratio of -9.90 and a beta of 0.06. The firm has a 50-day moving average price of $7.43 and a 200-day moving average price of $5.96.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.07). The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 28.81% and a negative net margin of 34.40%.

Cumberland Pharmaceuticals Dividend Announcement

The firm also recently declared a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 23rd were given a $1.50 dividend.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Several large investors have recently made changes to their positions in CPIX. BlackRock Inc. acquired a new stake in Cumberland Pharmaceuticals during the second quarter valued at approximately $412,000. Bank of New York Mellon Corp acquired a new stake in shares of Cumberland Pharmaceuticals during the second quarter worth $379,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Cumberland Pharmaceuticals during the first quarter valued at $66,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Cumberland Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company's stock valued at $898,000 after purchasing an additional 4,081 shares during the period. Institutional investors own 15.51% of the company's stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company headquartered in Nashville, Tennessee. Founded in 1999, the company develops, acquires, and commercializes branded prescription products, with an emphasis on hospital acute care, gastroenterology, and other specialty areas.

Its portfolio has included Caldolor, an intravenous formulation of ibuprofen used for pain and fever; Vaprisol, an injectable treatment for certain cases of hyponatremia; Kristalose, a prescription form of lactulose used to treat constipation; and Omeclamox-Pak, a therapy for Helicobacter pylori infection and associated ulcer disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.